Back to search

Democritus University of Thrace (DUTH)

Διερεύνηση της καρδιοτοξικότητας της τραστουζουμάμπης σε γυναίκες με μεταστατικό καρκίνο του μαστού

Abstract

dc:description

Introduction. Trastuzumab (Herceptin) is a monoclonal antibody that has been approved by PDA for the treatment of female patients with metastatic breast cancer and overexpression of HER2 receptors. In our institute Trastuzumab has been administered to such patients since 2000. lt has been observed that this treatment was accompanied with significant cardxotoxicitv such as heart failure and mitral valve insufficiency. Aim. The aim of the study was the determination of the incidence of cardiotoxicity during treatment with Trastuzumab and the investigation of its underlying mechanism(s). Patients. Fifty women with metastatic breast cancer, overexpression of HER2 receptors and no prior history of heart disease were treated with Herceptin (2mg/Kg/ week, after a loading dose of 4 mg/Kg) during the study. All patients had previously received six cycles of chemotherapy with the combination of Epirubicin. Fluouracil and Cyclophosphamide. Patients were eligible for study entry, if the time interval between the last chemotherapy cycle and treatment initiation with Herceptin, was at least 6 months. The median age of the patients was 51 years (range 30-68). Twenty healthy volunteers with a median age of 25,5 years (range 22-30) as well as 20 women with a median age of 42,5 years (range 25-65) diagnosed as having mammary fibroadenoma, all with no prior history of heart disease, were used as control groups. The median time of follow up was 18 months (range 9-41). Methods. Patient’s evaluation before study entry included the following: 1. case history and complete physical examination in order to exclude patients with heart disease or other health problems that could alter the results of subsequent examinations 2. electrocardiogram and echocardiogram 3. measurement of the blood levels of natriuretic peptide pro-BNP and proinflammatory cytokines (IL-1β, IL-2, IL-3, IL-4, IL-6, TNF-a, IL-8) Both control groups underwent the same clinical and laboratory evaluation. The follow up of the patients during therapy included weekly physical examination and electrocardiogram and monthly echocardiogram. Patients that during their weekly follow up visits presented with symptoms of heart failure were reevaluated with echocardiogram and determination of pro-BNP and proinflammatory cytokines blood levels at the time of the initial occurrence of the symptoms, as well as 2 and 6 months afterwards. These patients were subsequently treated for heart failure and in case of improvement, therapy with trastuzumab was resumed, while it was discontinued in case that the ejection fraction was < 40%.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2004

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Πλατογιάννης, Δημήτριος
  • Platogiannis, Dimitrios

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/17616

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Πλατογιάννης, Δημήτριος; Platogiannis, Dimitrios. Διερεύνηση της καρδιοτοξικότητας της τραστουζουμάμπης σε γυναίκες με μεταστατικό καρκίνο του μαστού. Democritus University of Thrace (DUTH), 2004. http://hdl.handle.net/10442/hedi/17616